カテゴリー： 世界, 医療/バイオ, Grand View Research

世界の医薬品原薬CDMO市場2023-2030：製品別（高活性API、抗体薬物複合体）、合成別、薬剤別、用途別、ワークフロー別、地域別

【英語タイトル】Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product (Highly Potent API, Antibody Drug Conjugate), By Synthesis, By Drug, By Application, By Workflow, By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23NOV025）・商品コード：GRV23NOV025
・発行会社（調査会社）：Grand View Research
・発行日：2023年9月
・ページ数：150
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：製薬
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

医薬品原薬CDMO市場の成長と動向
Grand View Research社の最新レポートによると、世界の医薬品原薬CDMO市場規模は2030年までに1,563億米ドルに達する見込みです。同市場は、2023年から2030年にかけて年平均成長率6.9%で拡大する見込みです。医薬品研究開発投資の増加、特許失効、ジェネリック医薬品需要の増加、アウトソーシングを推進する生物学的技術革新が市場を牽引する要因です。

低分子医薬品の増加、原薬（API）の複雑化、コスト削減の必要性が、医薬品分野におけるアウトソーシングサービスの急速な拡大に寄与しています。開発・製造受託機関（CDMO）分野で世界的な事業展開と規模拡大を実現している企業はごくわずかであり、まだ断片的です。また、多くの企業が原薬と製剤の統合ソースとしてワンストップショップのソリューションを提供しています。

ヘルスケア業界はダイナミックな変化の過程にあり、急速な技術進歩（自動化やAIなど）、CRO/CMO/CDMOのニーズ、研究投資の増加などの要因がヘルスケア市場に影響を与えています。活動のアウトソーシングは、業務効率の改善、地理的プレゼンスの拡大、リソースコストの削減、治療に関する専門知識の獲得、オンデマンドサービスの強化など、多くの製薬企業に利益をもたらしています。

COVID-19のパンデミックは、人工呼吸を必要とする重症患者の管理に必要な医薬品の需要が大幅に増加したことからも明らかなように、原薬メーカーにかつてない期待をかけました。その結果、急激な増産が必要になったことで、医薬品原薬CDMOには医薬品供給を維持するための適応能力が求められるようになりました。世界的な新しい治療法に対する需要の高まりと、パンデミック後の臨床研究の増加が、今後数年間の市場を支えるものと予想されます。

医薬品原薬CDMO市場レポートハイライト

- 伝統的な医薬品原薬セグメントが市場を支配し、2022年には39.8%の最大収益シェアを占めました。

- 革新的医薬品セグメントは2022年に73.7%の収益シェアを獲得。これは主に、新規分子体に対するFDA承認の増加、革新的API企業による研究開発への注力の増加によるものです。

- 2022年の売上高シェアはがん領域が35.5%でトップ。これは、がん治療用の高活性APIに対する需要の増加によるものです。

- バイオテクノロジー分野は、慢性疾患や感染症の治療にバイオ医薬品が多く採用されていることから、予測期間中に7.0%の急成長が見込まれます。

- 臨床ワークフロー分野は、予測期間中に最も速いCAGR 7.3%で成長すると予測されます。原薬の需要を支える臨床研究数の増加が、同分野の成長を促進する主な要因の1つです。

- アジア太平洋地域では、予測期間中に最も速いCAGR 9.1%を記録する見込みです。インドや中国などの発展途上国では、製薬会社や製造受託機関の数が非常に増加しているため、この地域は近い将来、欧州や北米を追い抜く可能性が高いです。

第1章 調査方法・範囲
第2章 エグゼクティブサマリー
第3章 世界の医薬品原薬CDMO市場変数・傾向・範囲
第4章 世界の医薬品原薬CDMO市場：製品別分析
第5章 世界の医薬品原薬CDMO市場：合成別分析
第6章 世界の医薬品原薬CDMO市場：薬剤別分析
第7章 世界の医薬品原薬CDMO市場：ワークフロー別分析
第8章 世界の医薬品原薬CDMO市場：用途別分析
第9章 世界の医薬品原薬CDMO市場：地域別分析
第10章　競争状況

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Synthesis
1.1.3. Drug
1.1.4. Application
1.1.5. Workflow
1.1.6. Regional scope
1.1.7. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Volume price analysis (Model 2)
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
1.9.3. Objective 3
1.9.4. Objective 4
Chapter 2. Executive Summary
2.1. Market Outlook
Chapter 3. Active Pharmaceutical Ingredients CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Increasing pharmaceutical R&D investment
3.3.1.2. Rising demand for generic drugs
3.3.1.3. Patent expiration
3.3.1.4. Expanding consumption of biopharmaceuticals
3.3.2. Market Restraint Analysis
3.3.2.1. Compliance issues while outsourcing
3.3.3. COVID-19 Impact & Recovery Analysis
3.3.4. Industry Analysis – Porter’s Five Forces
3.3.5. PESTLE Analysis
Chapter 4. Active Pharmaceutical Ingredients CDMO Market: Product Segment Analysis
4.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
4.2. Active Pharmaceutical Ingredients CDMO Market: Product Market Share Analysis, 2022 & 2030
4.3. Traditional Active Pharmaceutical Ingredient (Traditional API)
4.3.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market, 2018 – 2030 (USD Million)
4.4. Highly Potent Active Pharmaceutical Ingredient (HP-API)
4.4.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market, 2018 – 2030 (USD Million)
4.5. Antibody Drug Conjugate (ADC)
4.5.1. Antibody Drug Conjugate (ADC) Market, 2018 – 2030 (USD Million)
4.6. Others
4.6.1. Others Market, 2018 – 2030 (USD Million)
Chapter 5. Active Pharmaceutical Ingredients CDMO Market: Synthesis Segment Analysis
5.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
5.2. Active Pharmaceutical Ingredients CDMO Market: Synthesis Market Share Analysis, 2022 & 2030
5.3. Synthetic
5.3.1. Synthetic Market, 2018 – 2030 (USD Million)
5.4. Biotech
5.4.1. Biotech Market, 2018 – 2030 (USD Million)
Chapter 6. Active Pharmaceutical Ingredients CDMO Market: Drug Segment Analysis
6.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
6.2. Active Pharmaceutical Ingredients CDMO Market: Drug Market Share Analysis, 2022 & 2030
6.3. Innovative
6.3.1. Innovative Market, 2018 – 2030 (USD Million)
6.4. Generic
6.4.1. Generic Market, 2018 – 2030 (USD Million)
Chapter 7. Active Pharmaceutical Ingredients CDMO Market: Workflow Segment Analysis
7.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
7.2. Active Pharmaceutical Ingredients CDMO Market: Workflow Market Share Analysis, 2022 & 2030
7.3. Clinical
7.3.1. Clinical Market, 2018 – 2030 (USD Million)
7.4. Commercial
7.4.1. Commercial Market, 2018 – 2030 (USD Million)
Chapter 8. Active Pharmaceutical Ingredients CDMO Market: Application Segment Analysis
8.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
8.2. Active Pharmaceutical Ingredients CDMO Market: Application Market Share Analysis, 2022 & 2030
8.3. Oncology
8.3.1. Oncology Market, 2018 – 2030 (USD Million)
8.4. Hormonal
8.4.1. Hormonal Market, 2018 – 2030 (USD Million)
8.5. Glaucoma
8.5.1. Glaucoma Market, 2018 – 2030 (USD Million)
8.6. Cardiovascular
8.6.1. Cardiovascular Market, 2018 – 2030 (USD Million)
8.7. Diabetes
8.7.1. Diabetes Market, 2018 – 2030 (USD Million)
8.8. Others
8.8.1. Others Market, 2018 – 2030 (USD Million)
Chapter 9. Active Pharmaceutical Ingredients CDMO Market: Regional Analysis
9.1. Active Pharmaceutical Ingredients CDMO Regional market share analysis, 2022 & 2030
9.2. North America
9.2.1. North America Market estimates and forecast, 2018 – 2030
9.2.2. U.S.
9.2.2.1. U.S. Market estimates and forecast, 2018 – 2030
9.2.3. Canada
9.2.3.1. Canada Market estimates and forecast, 2018 – 2030
9.3. Europe
9.3.1. Europe Market estimates and forecast, 2018 – 2030
9.3.2. UK
9.3.2.1. UK Market estimates and forecast, 2018 – 2030
9.3.3. Germany
9.3.3.1. Germany Market estimates and forecast, 2018 – 2030
9.3.4. France
9.3.4.1. France Market estimates and forecast, 2018 – 2030
9.3.5. Italy
9.3.5.1. Italy Market estimates and forecast, 2018 – 2030
9.3.6. Spain
9.3.6.1. Spain Market estimates and forecast, 2018 – 2030
9.3.7. Denmark
9.3.7.1. Denmark Market estimates and forecast, 2018 – 2030
9.3.8. Sweden
9.3.8.1. Sweden Market estimates and forecast, 2018 – 2030
9.3.9. Norway
9.3.9.1. Norway Market estimates and forecast, 2018 – 2030
9.4. Asia Pacific
9.4.1. Asia Pacific Market estimates and forecast, 2018 – 2030
9.4.2. Japan
9.4.2.1. Japan Market estimates and forecast, 2018 – 2030
9.4.3. China
9.4.3.1. China Market estimates and forecast, 2018 – 2030
9.4.4. India
9.4.4.1. India Market estimates and forecast, 2018 – 2030
9.4.5. South Korea
9.4.5.1. South Korea Market estimates and forecast, 2018 – 2030
9.4.6. Australia
9.4.6.1. Australia Market estimates and forecast, 2018 – 2030
9.4.7. Thailand
9.4.7.1. Thailand Market estimates and forecast, 2018 – 2030
9.5. Latin America
9.5.1. Latin America Market estimates and forecast, 2018 – 2030
9.5.2. Brazil
9.5.2.1. Brazil Market estimates and forecast, 2018 – 2030
9.5.3. Mexico
9.5.3.1. Mexico Market estimates and forecast, 2018 – 2030
9.5.4. Argentina
9.5.4.1. Argentina Market estimates and forecast, 2018 – 2030
9.5.5. Colombia
9.5.5.1. Colombia Market estimates and forecast, 2018 – 2030
9.5.6. Chile
9.5.6.1. Chile Market estimates and forecast, 2018 – 2030
9.6. MEA
9.6.1. MEA Market estimates and forecast, 2018 – 2030
9.6.2. South Africa
9.6.2.1. South Africa Market Estimates and forecast, 2018 – 2030
9.6.3. Saudi Arabia
9.6.3.1. Saudi Arabia Market estimates and forecast, 2018 – 2030
9.6.4. UAE
9.6.4.1. UAE Market estimates and forecast, 2018 – 2030
9.6.5. Kuwait
9.6.5.1. Kuwait Market estimates and forecast, 2018 – 2030
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Strategy Mapping
10.3. Company Profiles/Listing
10.3.1. Cambrex Corporation
10.3.1.1. Overview
10.3.1.2. Financial Performance
10.3.1.3. Service Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. Recipharm AB
10.3.2.1. Overview
10.3.2.2. Financial Performance
10.3.2.3. Service Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. Thermo Fisher Scientific Inc. (Pantheon)
10.3.3.1. Overview
10.3.3.2. Financial Performance
10.3.3.3. Service Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. Samsung Biologics
10.3.4.1. Overview
10.3.4.2. Financial Performance
10.3.4.3. Service Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. Lonza
10.3.5.1. Overview
10.3.5.2. Financial Performance
10.3.5.3. Service Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. Catalent, Inc.
10.3.6.1. Overview
10.3.6.2. Financial Performance
10.3.6.3. Service Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. Siegfried Holding AG
10.3.7.1. Overview
10.3.7.2. Financial Performance
10.3.7.3. Service Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. Piramal Pharma Solutions
10.3.8.1. Overview
10.3.8.2. Financial Performance
10.3.8.3. Service Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Boehringer Ingelheim
10.3.9.1. Overview
10.3.9.2. Financial Performance
10.3.9.3. Service Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. CordenPharma International
10.3.10.1. Overview
10.3.10.2. Financial Performance
10.3.10.3. Service Benchmarking
10.3.10.4. Strategic Initiatives

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 4 Global active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 5 Global active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 6 Global active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 7 Global active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 8 Global active pharmaceutical ingredient CDMO market, by region, 2018 - 2030 (USD Million)
Table 9 North America active pharmaceutical ingredient CDMO market, by country, 2018 - 2030 (USD Million)
Table 10 North America active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 11 North America active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 12 North America active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 13 North America active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 14 North America active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 15 U.S. active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 16 U.S. active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 17 U.S. active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 18 U.S. active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 19 U.S. active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 20 Canada active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 21 Canada active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 22 Canada active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 23 Canada active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 24 Canada active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 25 Europe active pharmaceutical ingredient CDMO market, by country, 2018 - 2030 (USD Million)
Table 26 Europe active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 27 Europe active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 28 Europe active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 29 Europe active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 30 Europe active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 31 Germany active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 32 Germany active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 33 Germany active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 34 Germany active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 35 Germany active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 36 UK active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 37 UK active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 38 UK active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 39 UK active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 40 UK active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 41 France active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 42 France active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 43 France active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 44 France active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 45 France active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 46 Italy active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 47 Italy active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 48 Italy active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 49 Italy active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 50 Italy active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 51 Spain active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 52 Spain active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 53 Spain active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 54 Spain active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 55 Spain active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 56 Denmark active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 57 Denmark active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 58 Denmark active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 59 Denmark active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 60 Denmark active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 61 Sweden active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 62 Sweden active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 63 Sweden active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 64 Sweden active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 65 Sweden active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 66 Norway active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 67 Norway active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 68 Norway active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 69 Norway active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 70 Norway active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 71 Asia Pacific active pharmaceutical ingredient CDMO market, by country, 2018 - 2030 (USD Million)
Table 72 Asia Pacific active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 73 Asia Pacific active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 74 Asia Pacific active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 75 Asia Pacific active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 76 Asia Pacific active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 77 Japan active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 78 Japan active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 79 Japan active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 80 Japan active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 81 Japan active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 82 China active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 83 China active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 84 China active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 85 China active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 86 China active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 87 India active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 88 India active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 89 India active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 90 India active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 91 India active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 92 Australia active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 93 Australia active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 94 Australia active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 95 Australia active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 96 Australia active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 97 South Korea active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 98 South Korea active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 99 South Korea active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 100 South Korea active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 101 South Korea active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 102 Thailand active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 103 Thailand active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 104 Thailand active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 105 Thailand active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 106 Thailand active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million
Table 107 Latin America active pharmaceutical ingredient CDMO market, by country, 2018 - 2030 (USD Million)
Table 108 Latin America active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 109 Latin America active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 110 Latin America active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 111 Latin America active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 112 Latin America active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 113 Brazil active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 114 Brazil active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 115 Brazil active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 116 Brazil active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 117 Brazil active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 118 Mexico active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 119 Mexico active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 120 Mexico active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 121 Mexico active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 122 Mexico active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 123 Argentina active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 124 Argentina active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 125 Argentina active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 126 Argentina active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 127 Argentina active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 128 Colombia active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 129 Colombia active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 130 Colombia active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 131 Colombia active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 132 Colombia active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 133 Chile active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 134 Chile active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 135 Chile active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 136 Chile active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 137 Chile active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 138 Middle East & Africa active pharmaceutical ingredient CDMO market, by country, 2018 - 2030 (USD Million)
Table 139 Middle East & Africa active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 140 Middle East & Africa active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 141 Middle East & Africa active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 142 Middle East & Africa active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 143 Middle East & Africa active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 144 South Africa active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 145 South Africa active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 146 South Africa active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 147 South Africa active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 148 South Africa active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 149 Saudi Arabia active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 150 Saudi Arabia active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 151 Saudi Arabia active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 152 Saudi Arabia active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 153 Saudi Arabia active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 154 UAE active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 155 UAE active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 156 UAE active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 157 UAE active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 158 UAE active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 159 Kuwait active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 160 Kuwait active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 161 Kuwait active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 162 Kuwait active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 163 Kuwait active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Market formulation & validation
Fig. 6 Commodity flow analysis
Fig. 7 Active Pharmaceutical Ingredients CDMO market snapshot (2020)
Fig. 8 Active Pharmaceutical Ingredients CDMO market segmentation
Fig. 9 Parent market outlook
Fig. 10 Penetration & growth prospect mapping
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 FDA approval and biosimilar product launch trends from 2015 to 2020.
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Porter’s Five Forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Active Pharmaceutical Ingredients CDMO market Product outlook: Segment dashboard
Fig. 17 Active Pharmaceutical Ingredients CDMO market: Product movement analysis
Fig. 18 Traditional API market, 2018 - 2030 (USD Million)
Fig. 19 HP-API market, 2018 - 2030 (USD Million)
Fig. 20 Antibody-drug conjugate market, 2018 - 2030 (USD Million)
Fig. 21 Others market, 2018 - 2030 (USD Million)
Fig. 22 Active Pharmaceutical ingredients CDMO market synthesis outlook: segment dashboard
Fig. 23 Active pharmaceutical ingredients CDMO market: synthesis movement analysis
Fig. 24 Synthetic market, 2018 - 2030 (USD Million)
Fig. 25 Biotech market, 2018 - 2030 (USD Million)
Fig. 26 Active pharmaceutical ingredients CDMO market drug outlook: segment dashboard
Fig. 27 Active pharmaceutical ingredients CDMO market: drug movement analysis
Fig. 28 Innovative market, 2018 - 2030 (USD Million)
Fig. 29 Generics market, 2018 - 2030 (USD Million)
Fig. 30 Active pharmaceutical ingredients CDMO market application outlook: segment dashboard
Fig. 31 Active pharmaceutical ingredients CDMO market: application movement analysis
Fig. 32 Oncology market, 2018 - 2030 (USD Million)
Fig. 33 Hormonal market, 2018 - 2030 (USD Million)
Fig. 34 Glaucoma market, 2018 - 2030 (USD Million)
Fig. 35 Cardiovascular disease market, 2018 - 2030 (USD Million)
Fig. 36 Diabetes market, 2018 - 2030 (USD Million)
Fig. 37 Others market, 2018 - 2030 (USD Million)
Fig. 38 Active pharmaceutical ingredients CDMO market workflow outlook: segment dashboard
Fig. 39 Active pharmaceutical ingredients CDMO market: workflow movement analysis
Fig. 40 Clinical market, 2018 - 2030 (USD Million)
Fig. 41 Commercial market, 2018 - 2030 (USD Million)
Fig. 42 Regional market: Key takeaways
Fig. 43 Active Pharmaceutical Ingredients CDMO market: Regional movement analysis
Fig. 44 North America market, 2018 - 2030 (USD Million)
Fig. 45 U.S. market, 2018 - 2030 (USD Million)
Fig. 46 Canada market, 2018 - 2030 (USD Million)
Fig. 47 Europe market, 2018 - 2030 (USD Million)
Fig. 48 UK market, 2018 - 2030 (USD Million)
Fig. 49 Germany market, 2018 - 2030 (USD Million)
Fig. 50 France market, 2018 - 2030 (USD Million)
Fig. 51 Italy market, 2018 - 2030 (USD Million)
Fig. 52 Spain market, 2018 - 2030 (USD Million)
Fig. 53 Denmark market, 2018 - 2030 (USD Million)
Fig. 54 Sweden market, 2018 - 2030 (USD Million)
Fig. 55 Norway market, 2018 - 2030 (USD Million)
Fig. 56 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 57 India market, 2018 - 2030 (USD Million)
Fig. 58 Japan market, 2018 - 2030 (USD Million)
Fig. 59 China market, 2018 - 2030 (USD Million)
Fig. 60 Australia market, 2018 - 2030 (USD Million)
Fig. 61 South Korea market, 2018 - 2030 (USD Million)
Fig. 62 Thailand market, 2018 - 2030 (USD Million)
Fig. 63 Latin America market, 2018 - 2030 (USD Million)
Fig. 64 Brazil market, 2018 - 2030 (USD Million)
Fig. 65 Mexico market, 2018 - 2030 (USD Million)
Fig. 66 Argentina market, 2018 - 2030 (USD Million)
Fig. 67 Colombia market, 2018 - 2030 (USD Million)
Fig. 68 Chile market, 2018 - 2030 (USD Million)
Fig. 69 MEA market, 2018 - 2030 (USD Million)
Fig. 70 South Africa market, 2018 - 2030 (USD Million)
Fig. 71 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 72 UAE market, 2018 - 2030 (USD Million)
Fig. 73 Kuwait market, 2018 - 2030 (USD Million)  

★調査レポート[世界の医薬品原薬CDMO市場2023-2030：製品別（高活性API、抗体薬物複合体）、合成別、薬剤別、用途別、ワークフロー別、地域別] (コード：GRV23NOV025)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の医薬品原薬CDMO市場2023-2030：製品別（高活性API、抗体薬物複合体）、合成別、薬剤別、用途別、ワークフロー別、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の医薬品CDMO市場2023-2030：製品別（API、医薬品）、ワークフロー別（臨床、商業）、用途別（腫瘍、ホルモン、緑内障、心血管疾患、糖尿病、その他）、地域別
  • 世界のDNAシーケンス市場2023-2030：製品・サービス別（消耗品、機器）、用途別（腫瘍学、HLAタイピング）、技術別、ワークフロー別、エンドユーザー別、地域別
  • 世界の自動＆閉鎖型細胞治療処理システム市場2023-2030：ワークフロー別（分離、拡張、アフェレーシス）、種類別、スケール別、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆